Abstract
3/2025
vol. 11
Review paper
Recommendations for hypolipidemic and antithrombotic therapy in HCV-infected patients treated with direct-acting antiviral agents: expert position statement
Jerzy Jaroszewicz
1
,
Marlena Broncel
2
,
Anna Piekarska
3
,
Filip M. Szymanski
4
,
Krzysztof Tomasiewicz
5
,
Paweł Rajewski
6
,
Maciej Banach
7, 8
,
Bartosz Hudzik
9, 10
,
Mariusz Gąsior
9
,
Robert Flisiak
11
,
Robert Gil
12
- Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, Poland
- Department of Internal Medicine and Clinical Pharmacology, Medical University of Lodz, Centre for the Treatment of Lipid Disorders, Łódź, Poland
- Department of Infectious Diseases and Hepatology, Medical University of Lodz, Łódź, Poland
- Department of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland
- Department of Infectious Diseases and Hepatology, USK-1, Medical University of Lublin, Lublin, Poland
- Department of Internal and Infectious Diseases, Provincial Infectious Disease Hospital, Bydgoszcz, Poland
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland
- Faculty of Medicine, John Paul II Catholic University of Lublin, Lublin, Poland
- 3rd Department and Clinical Department of Cardiology, Faculty of Medicine with Division of Medicine and Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland
- Department of Cardiovascular Prevention, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, Poland
- Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland
- National Medical Institute of the Internal Affairs and Administration Ministry, Warsaw, Poland
Clin Exp HEPATOL 2025; 11, 3: 205–218
Online publish date: 2025/09/30
The recently observed increase in cardiovascular disease incidence in patients with chronic hepatitis C has contributed to hepatitis C virus (HCV) being considered a new, non-classical risk factor. HCV infection may also lead to the development of metabolic disorders, which play an important role in the development of cardiovascular diseases. The notable impact of HCV on the development of obesity, insulin resistance, diabetes, lipid disorders and fatty liver has led to metabolic disorders in the course of HCV infection being referred to as metabolic-viral syndrome. On the other hand, modern treatment of HCV infection with direct-acting antiviral drugs is extremely effective and safe, while drug interactions are the main potential limitation. This article presents expert recommendations for the diagnosis and treatment of heart disease and lipid disorders in HCV-infected patients.
Keywords
anticoagulants, HCV infection, lipid-lowering drugs, direct-acting antivirals, cardiovascular diseases
Coverage in
Integrated with
